Fennec Pharmaceuticals (FENC) News Today $6.50 +0.04 (+0.62%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$6.51 +0.01 (+0.15%) As of 03/28/2025 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Rosalind Advisors Inc. Buys Shares of 1,259,876 Fennec Pharmaceuticals Inc (NASDAQ:FENC)Rosalind Advisors Inc. purchased a new stake in Fennec Pharmaceuticals Inc (NASDAQ:FENC - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,259,876 shares of the company's stock, valuedMarch 23, 2025 | marketbeat.comClayton Partners LLC Acquires Shares of 40,540 Fennec Pharmaceuticals Inc (NASDAQ:FENC)Clayton Partners LLC acquired a new position in shares of Fennec Pharmaceuticals Inc (NASDAQ:FENC - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 40,540 shares of the company's stock, valuMarch 17, 2025 | marketbeat.comEquities Analysts Offer Predictions for FENC Q1 EarningsFennec Pharmaceuticals Inc (NASDAQ:FENC - Free Report) - Equities research analysts at HC Wainwright boosted their Q1 2025 EPS estimates for Fennec Pharmaceuticals in a research note issued on Tuesday, March 11th. HC Wainwright analyst R. Selvaraju now expects that the company will post earningsMarch 14, 2025 | marketbeat.comWedbush Expects Higher Earnings for Fennec PharmaceuticalsFennec Pharmaceuticals Inc (NASDAQ:FENC - Free Report) - Equities researchers at Wedbush raised their Q1 2025 earnings per share estimates for Fennec Pharmaceuticals in a report issued on Monday, March 10th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of ($March 14, 2025 | marketbeat.comWedbush Analysts Increase Earnings Estimates for FENCFennec Pharmaceuticals Inc (NASDAQ:FENC - Free Report) - Wedbush increased their FY2025 earnings estimates for shares of Fennec Pharmaceuticals in a report released on Monday, March 10th. Wedbush analyst D. Nierengarten now expects that the company will post earnings of $0.55 per share for the yeMarch 13, 2025 | marketbeat.comFennec Pharmaceuticals (FENC) Projected to Post Quarterly Earnings on ThursdayFennec Pharmaceuticals (NASDAQ:FENC) will be releasing earnings before the market opens on Thursday, March 20, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=673323)March 13, 2025 | marketbeat.comHC Wainwright Reiterates Buy Rating for Fennec Pharmaceuticals (NASDAQ:FENC)HC Wainwright reiterated a "buy" rating and set a $13.00 price target on shares of Fennec Pharmaceuticals in a research note on Tuesday.March 12, 2025 | marketbeat.comFennec Pharmaceuticals (NASDAQ:FENC) Earns Outperform Rating from WedbushWedbush reaffirmed an "outperform" rating and set a $13.00 price target on shares of Fennec Pharmaceuticals in a report on Monday.March 11, 2025 | marketbeat.comFennec Pharmaceuticals Inc. (NASDAQ:FENC) Q4 2024 Earnings Call TranscriptMarch 11, 2025 | insidermonkey.comFennec Pharmaceuticals Inc (FENC) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...March 11, 2025 | gurufocus.comQ4 2024 Fennec Pharmaceuticals Inc Earnings Call TranscriptMarch 11, 2025 | gurufocus.comFennec Pharmaceuticals Shares Down After 4Q ResultsMarch 10, 2025 | marketwatch.comInvesting in Fennec Pharmaceuticals (NASDAQ:FENC) five years ago would have delivered you a 38% gainMarch 10, 2025 | finance.yahoo.comFennec Pharmaceuticals Inc. (FENC) Q4 2024 Earnings Call TranscriptMarch 10, 2025 | seekingalpha.comFennec Pharmaceuticals (NASDAQ:FENC) Announces Earnings ResultsFennec Pharmaceuticals (NASDAQ:FENC - Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.06) EPS for the quarter, missing analysts' consensus estimates of $0.56 by ($0.62). Fennec Pharmaceuticals had a negative return on equity of 53.38% and a negative net margin of 2.30%.March 10, 2025 | marketbeat.comFennec Pharmaceuticals Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business UpdateMarch 10, 2025 | globenewswire.comFennec Pharmaceuticals (FENC) Projected to Post Quarterly Earnings on MondayFennec Pharmaceuticals (NASDAQ:FENC) will be releasing earnings before the market opens on Monday, March 10, Financial Modeling Prep reports.March 8, 2025 | marketbeat.comRosty Raykov Sells 10,000 Shares of Fennec Pharmaceuticals Inc (NASDAQ:FENC) StockFennec Pharmaceuticals Inc (NASDAQ:FENC - Get Free Report) Director Rosty Raykov sold 10,000 shares of the business's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $6.79, for a total value of $67,900.00. Following the transaction, the director now owns 68,725 shares of the company's stock, valued at approximately $466,642.75. This trade represents a 12.70 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.March 7, 2025 | marketbeat.comFennec Pharmaceuticals to Report Full Year and Fourth Quarter 2024 Financial Results on March 10, 2025March 6, 2025 | financialpost.comFennec Pharmaceuticals to Report Full Year and Fourth Quarter 2024 Financial Results on March 10, 2025March 6, 2025 | globenewswire.comDG Capital Management, LLC Reduces Stake in Fennec Pharmaceuticals IncFebruary 14, 2025 | gurufocus.comFennec Pharmaceuticals Inc.: Fennec Pharmaceuticals Announces Commercial Launch of PEDMARQSI In GermanyFebruary 8, 2025 | finanznachrichten.deFennec announces commercial launch of PEDMARQSI in GermanyFebruary 7, 2025 | markets.businessinsider.comNorgine introduces PEDMARQSI in Germany for pediatric cancer careFebruary 7, 2025 | msn.comFennec Pharmaceuticals Announces Commercial Launch of PEDMARQSI® In GermanyFebruary 7, 2025 | globenewswire.comInsider Selling: Fennec Pharmaceuticals Inc (NASDAQ:FENC) Director Sells 10,000 Shares of StockFebruary 6, 2025 | insidertrades.comFennec Pharmaceuticals director Raykov sells $66,600 in sharesFebruary 5, 2025 | msn.comFennec Pharmaceuticals Inc (NASDAQ:FENC) Director Sells $66,600.00 in StockFennec Pharmaceuticals Inc (NASDAQ:FENC - Get Free Report) Director Rosty Raykov sold 10,000 shares of the stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $6.66, for a total value of $66,600.00. Following the sale, the director now directly owns 76,294 shares in the company, valued at $508,118.04. This trade represents a 11.59 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.February 5, 2025 | marketbeat.comFennec Pharmaceuticals Inc (NASDAQ:FENC) Short Interest Down 6.2% in JanuaryFennec Pharmaceuticals Inc (NASDAQ:FENC - Get Free Report) was the target of a large drop in short interest in the month of January. As of January 15th, there was short interest totalling 1,980,000 shares, a drop of 6.2% from the December 31st total of 2,110,000 shares. Based on an average trading volume of 118,500 shares, the short-interest ratio is presently 16.7 days. Approximately 8.7% of the shares of the company are short sold.February 1, 2025 | marketbeat.comFennec Pharmaceuticals Inc (NASDAQ:FENC) Sees Large Decrease in Short InterestFennec Pharmaceuticals Inc (NASDAQ:FENC - Get Free Report) saw a large decline in short interest in December. As of December 31st, there was short interest totalling 1,980,000 shares, a decline of 6.2% from the December 15th total of 2,110,000 shares. Based on an average daily trading volume, of 118,500 shares, the short-interest ratio is currently 16.7 days. Currently, 8.7% of the shares of the stock are sold short.January 19, 2025 | marketbeat.comFennec's Pedmarqsi gets nod from U.K. regulatorsDecember 20, 2024 | msn.comFennec announces Pedmarqsi positive recommendation by NICEDecember 20, 2024 | markets.businessinsider.comFennec Pharmaceuticals (NASDAQ:FENC) Given Outperform Rating at WedbushWedbush reiterated an "outperform" rating and issued a $13.00 price objective on shares of Fennec Pharmaceuticals in a research report on Friday.December 20, 2024 | marketbeat.comFennec' Pedmarqsi Gets Support From NICE For Cisplatin-Induced Hearing Loss PreventionDecember 20, 2024 | markets.businessinsider.comFennec Pharmaceuticals Announces Pedmarqsi® Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and WalesDecember 20, 2024 | globenewswire.comHC Wainwright Has Bearish Forecast for FENC FY2024 EarningsFennec Pharmaceuticals Inc (NASDAQ:FENC - Free Report) - HC Wainwright lowered their FY2024 earnings estimates for Fennec Pharmaceuticals in a report issued on Tuesday, December 17th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($0.13) per share for the year, downDecember 19, 2024 | marketbeat.comFennec Pharmaceuticals Announces Early Partial Repayment of Its Outstanding Convertible Debt Facility with Petrichor Healthcare Capital ManagementDecember 19, 2024 | globenewswire.comOptimistic Growth Prospects for Fennec Pharmaceuticals Amidst Financial ChallengesDecember 18, 2024 | markets.businessinsider.comFennec Pharmaceuticals' (FENC) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $13.00 price target on shares of Fennec Pharmaceuticals in a research report on Tuesday.December 17, 2024 | marketbeat.comFennec Pharmaceuticals to Participate in Upcoming Investor ConferenceDecember 12, 2024 | financialpost.comFennec Pharmaceuticals to Participate in Upcoming Investor ConferenceDecember 12, 2024 | financialpost.comFennec Pharmaceuticals to Participate in Upcoming Investor ConferenceDecember 12, 2024 | globenewswire.comInsider Sell: Rosty Raykov Sells Shares of Fennec Pharmaceuticals Inc (FENC)December 4, 2024 | gurufocus.comFennec Pharmaceuticals Inc (NASDAQ:FENC) Director Sells $39,351.26 in StockDecember 3, 2024 | insidertrades.comFennec Pharmaceuticals (NASDAQ:FENC) Rating Increased to Strong-Buy at StephensStephens raised Fennec Pharmaceuticals to a "strong-buy" rating in a research note on Monday.November 20, 2024 | marketbeat.comFennec initiated with an Overweight at StephensNovember 18, 2024 | markets.businessinsider.comFennec Pharmaceuticals to Participate in Upcoming Investor ConferenceNovember 13, 2024 | globenewswire.comFennec Pharmaceuticals Inc. (NASDAQ:FENC) Q3 2024 Earnings Call TranscriptNovember 11, 2024 | msn.comResearch Analysts Offer Predictions for FENC FY2025 EarningsFennec Pharmaceuticals Inc (NASDAQ:FENC - Free Report) - Research analysts at Wedbush cut their FY2025 earnings estimates for shares of Fennec Pharmaceuticals in a note issued to investors on Thursday, November 7th. Wedbush analyst D. Nierengarten now anticipates that the company will earn $0.05November 11, 2024 | marketbeat.comFennec Pharmaceuticals Inc. (FENC) Q3 2024 Earnings Call TranscriptNovember 9, 2024 | seekingalpha.com Remove Ads Get Fennec Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for FENC and its competitors with MarketBeat's FREE daily newsletter. Email Address FENC Media Mentions By Week FENC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FENC News Sentiment▼1.550.80▲Average Medical News Sentiment FENC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FENC Articles This Week▼32▲FENC Articles Average Week Remove Ads Get Fennec Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for FENC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MeiraGTx News Valneva News Immatics News Sana Biotechnology News Relay Therapeutics News Opthea News Maze Therapeutics News Cullinan Therapeutics News Autolus Therapeutics News Tourmaline Bio News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FENC) was last updated on 3/29/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fennec Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Fennec Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
